| Patent(s) and the Corresponding Patented Drug(s) |
Top |
| World Intellectual Property Organization (WIPO) |
| Patent ID |
WO2014011573 |
| Title |
Oligonucleotide Inhibitors of Dna Methyltransferases and Their Use In Treating Diseases. |
| Abstract |
Modified oligonucleotides comprising CpG sites, wherein the cytosine is replaced by cytosine analogs are provided as well as methods of making the oligonucleotides and their use in inhibiting DNA Methyltransferase, inhibiting or reversing methylation of genes and in treating cancer, tumorigenesis and hyper-proliferative disorders. |
| Applicant(s) |
Metheor Therapeutics Corporation |
| Representative Drug(s) |
D04LBL |
Drug Info
|
N.A. |
[1] |
| Patent ID |
WO2012142480 |
| Title |
Chimeric Rna Oligonucleotides and Uses Thereof. |
| Abstract |
The present invention relates to chimeric RNA oligonucleotides that are single-stranded oligonucleotides. These compounds are capable of targeting particular genes and reducing DNA methyltransferase activity. Accordingly, these compounds are particularly useful in the treatment of disease associated with aberrant DNA methyltransferase activity, such as cancer or a genetic disorder. |
| Applicant(s) |
Beth Israel Deaconess Medical Center Inc |
| Representative Drug(s) |
D05NMG |
Drug Info
|
N.A. |
[1] |
| United States Patent and Trademark Office (USPTO) |
| Patent ID |
US20140171492 |
| Title |
Chimeric Rna Oligonucleotides and Uses Thereof. |
| Representative Drug(s) |
D05NMG |
Drug Info
|
N.A. |
[1] |
